Enable Injections, based in Cincinnati, finished its first in-human pilot trial of a wearable injector technology platform that allows patients to self-administer drugs subcutaneously.
The trial included 10 patients who were their own controls. They self-administered four doses of saline.
Here are five notes:
1. The pilot trial measured dose delivery, injection pain and ease of use.
2. The Enable Injector successfully delivered low (1.5 mL) and high (2 of 10 mL) doses of saline.
3. Designed to simplify the issues of patient compliance and high costs of delivering large volume drugs, the Enable Injector was created with the knowledge of many human factors studies.
4. The technology is designed to be safe and comfortable for patients, while maintaining cost-effectiveness for the pharmaceutical industry and payers.
5. Enable Injections has feasibility and collaboration programs with pharmaceutical and biotechnology companies.
"An easy to use, relatively painless injector like this may open the door not only for new pharmaceuticals that may not be possible without this type of device, but also significantly improve patient compliance," said Gary Ansel, MD, principal investigator and associate medical director of the OhioHealth Research and Innovation Institute in Columbus.
